You are here

  • Home
  • Archive
  • Volume 92, Issue 5
  • Plasma microRNA signature as biomarker for disease progression in frontotemporal dementia and amyotrophic lateral sclerosis

Article Text

Article menu
Download PDFPDF
Editorial commentary
Plasma microRNA signature as biomarker for disease progression in frontotemporal dementia and amyotrophic lateral sclerosis
  1. Ramita Dewan1,
  2. Bryan J Traynor1,2,3
  1. 1 Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA
  2. 2 Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA
  3. 3 Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK
  1. Correspondence to Dr Bryan J Traynor, Laboratory of Neurogenetics (NIA/NIH), National Institutes of Health, Bethesda, Maryland 20892-3707, USA; traynorb{at}mail.nih.gov

https://doi.org/10.1136/jnnp-2020-325478

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Four miRNAs are differentially expressed in plasma between C9orf72-associated clinical conditions

    Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are increasingly recognised as constituting a spectrum of neurodegenerative disease. The C9orf72 intronic hexanucleotide repeat expansion is the most common genetic cause of FTD and ALS, accounting for about 1 in 10 of all cases, respectively.1 Though limited treatment options can provide a marginally decreased rate of disease progression, there is no current treatment that effectively halts neurodegeneration. However, recent advances have contributed to the development of antisense oligonucleotides targeting the C9orf72 repeat expansion with promising preliminary results.2

    As we continue to elucidate the genetic basis of disease for FTD and ALS and progress towards therapeutic development, it is important to identify biomarkers to assess …

    View Full Text

    Footnotes

    • Contributors RD and BJT wrote the manuscript.

    • Funding This research was supported by the Intramural Research Program of the National Institutes of Health (National Institute on Aging, project number: 1ZIAAG000935 (PI Bryan J Traynor)).

    • Competing interests BJT holds US, EU and Canadian patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of C9orf72. BJT is an editorial board member for JNNP and Neurobiology of Aging and is an associate editor for Brain.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Neurodegeneration
      Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis
      Virgilio Kmetzsch Vincent Anquetil Dario Saracino Daisy Rinaldi Agnès Camuzat Thomas Gareau Ludmila Jornea Sylvie Forlani Philippe Couratier David Wallon Florence Pasquier Noémie Robil Pierre de la Grange Ivan Moszer Isabelle Le Ber Olivier Colliot Emmanuelle Becker The PREV-DEMALS study group Eve Benchetrit Anne Bertrand Anne Bissery Marie-Paule Boncoeur Stéphanie Bombois Agnès Camuzat Mathieu Chastan Yaohua Chen Marie Chupin Olivier Colliot Philippe Couratier Xavier Delbeuck Vincent Deramecourt Christine Delmaire Emmanuel Gerardin Claude Hossein-Foucher Bruno Dubois Marie-Odile Habert Didier Hannequin Géraldine Lautrete Thibaud Lebouvier Isabelle Le Ber Benjamin Le Toullec Richard Levy Olivier Martinaud Kelly Martineau Marie-Anne Mackowiak Jacques Monteil Florence Pasquier Gregory Petyt Pierre-François Pradat Assi-Hervé Oya Armelle Rametti-Lacroux Daisy Rinaldi Adeline Rollin-Sillaire François Salachas Sabrina Sayah David Wallon
      Journal of Neurology, Neurosurgery & Psychiatry 2020; 92 485-493 Published Online First: 25 Nov 2020. doi: 10.1136/jnnp-2020-324647